Shanzhi Gu

机构：Central South University, Hunan Cancer Hospital, Xi'an Jiaotong University · ORCID：0000-0001-6099-4543

发表论文 99 篇 · 总被引 5928 次 · h-index 29

代表论文

• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial (2024 · Journal of Clinical Oncology · 被引 48)
• LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) (2025 · Annals of Oncology · 被引 38)
• Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. (2024 · Journal of Clinical Oncology · 被引 35)
• Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) (2024 · Journal of Cachexia Sarcopenia and Muscle · 被引 15)
• Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study (2025 · Journal of Hepatology · 被引 14)
• Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE). (2025 · Journal of Clinical Oncology · 被引 13)